This article explains what albendazole actually does for strongyloidiasis, what the clinical trial evidence shows about how well it works compared with the alternative treatment, how it is dosed when a physician chooses to use it, and what a patient should realistically expect during and after a course. The short answer is that albendazole does have activity against Strongyloides stercoralis, but it is not the first-choice drug in most current guidelines—and understanding why matters for anyone making a treatment decision with their doctor.

What strongyloidiasis is, and why the right drug matters

Strongyloides stercoralis is a soil-transmitted roundworm found in warm, moist regions of the tropics and subtropics, including parts of Southeast Asia, sub-Saharan Africa, Latin America, and historically in some rural areas of the southeastern United States. Larvae in contaminated soil penetrate the skin, usually through bare feet, migrate through the bloodstream and lungs, and settle in the small intestine as adult worms. Many infected people have no symptoms at all, or only mild ones—abdominal discomfort, intermittent diarrhea, an itchy migratory rash, or unexplained eosinophilia on a routine blood count.

What sets this parasite apart from most other intestinal worms is its capacity for autoinfection: larvae can mature and reinvade the same host internally, allowing the infection to persist quietly for decades without new exposure. This is a striking, almost unsettling feature of how the organism is built, and it is precisely why the body's design deserves respect rather than casual assumptions—an infection that seems trivial can remain dormant for a lifetime and become dangerous the moment a person's immune defenses are lowered, for instance by corticosteroids, chemotherapy, or organ transplantation. In that setting, the worm burden can explode into hyperinfection syndrome or disseminated disease, which carries a substantial risk of death if not recognized and treated promptly. This is the central reason strongyloidiasis is worth taking seriously even when it looks mild, and why anyone with a history of residence or extended travel in an endemic region should mention that to their doctor before starting immunosuppressive treatment.

The evidence: how albendazole compares with the preferred treatment

Albendazole belongs to the benzimidazole class of anthelmintics. It works by binding to a structural protein called beta-tubulin inside the worm's cells, disrupting the microtubules the parasite needs to absorb nutrients, which effectively starves it. This mechanism is well established from decades of laboratory and clinical work and is not in dispute.

What is well established, and worth stating plainly, is that albendazole is less effective against Strongyloides than ivermectin. A randomized trial conducted in Zanzibar in the mid-1990s, published in the American Journal of Tropical Medicine and Hygiene, compared a single dose of ivermectin against a short course of albendazole in children with soil-transmitted helminth infections, including strongyloidiasis, and found cure rates clearly favoring ivermectin over albendazole. That trial, along with several smaller studies from the same era, formed the basis of a Cochrane systematic review—first published in the early 2010s and updated in 2016—that pooled the randomized evidence comparing ivermectin with albendazole or thiabendazole for Strongyloides infection. The Cochrane authors concluded, with moderate-certainty evidence, that ivermectin achieves substantially higher parasitological cure rates than albendazole, with a more favorable side-effect profile as well.

For that reason, the Centers for Disease Control and Prevention and most infectious disease treatment guidelines list ivermectin as the drug of choice for strongyloidiasis, with albendazole reserved as an alternative—used when ivermectin is unavailable, not tolerated, or contraindicated, or sometimes added alongside ivermectin in severe disseminated disease. It is also worth noting, in the interest of full accuracy, that in the United States albendazole's FDA-approved indications are neurocysticercosis and hydatid (echinococcal) disease; its use for strongyloidiasis is an accepted but technically off-label application, supported by clinical guidelines and decades of use rather than by an FDA label specific to this parasite. Patients should understand that distinction, not because it makes the drug unsafe, but because informed consent means knowing exactly what a prescription is and is not officially indicated for.

Dosing: how albendazole is actually prescribed for this infection

When albendazole is used for strongyloidiasis, the regimen differs from the shorter courses used for common intestinal worms like pinworm or roundworm. The typical adult dose is 400 mg taken by mouth twice daily for seven days—a notably longer course than the single dose or three-day regimen used for most other soil-transmitted helminths, reflecting the parasite's autoinfective life cycle and the drug's comparatively modest efficacy against it.

Because a single course does not reliably eliminate every larva, some clinicians repeat the regimen or reassess with ivermectin rather than assuming one week of albendazole has closed the matter. This is a place where working closely with a physician who understands the parasite's biology—rather than treating the prescription as a one-off errand—genuinely changes the outcome.

What to expect: timeline, side effects, and confirming a cure

Patients often ask how quickly albendazole "works." Symptomatic relief—less bloating, better bowel habits, resolution of the migratory rash sometimes called larva currens—can begin within days as the worm burden falls. But symptom improvement is not the same as cure, and Strongyloides is notoriously difficult to confirm as eradicated. A single stool examination has poor sensitivity, often missing the infection outright, so guidelines call for multiple stool samples over time, and many clinicians also rely on serology—a blood test measuring antibodies against the parasite. Antibody levels decline slowly after successful treatment, over months rather than days, so a follow-up serologic test is usually done no sooner than six months after treatment to judge whether the infection has genuinely cleared. A falling eosinophil count on a routine blood test is a helpful supporting sign, though not proof on its own.

Albendazole is generally well tolerated for short courses. Reported side effects include:

Albendazole is not recommended in pregnancy, particularly in the first trimester, based on findings of harm in animal reproduction studies; a physician will weigh the risks and timing carefully, and in most non-urgent cases treatment is deferred until after delivery. This is a straightforward example of why self-treatment with leftover or online-sourced medication is unwise—dosing and timing decisions genuinely depend on a person's specific medical situation, and a physician overseeing the full picture protects both mother and child.

Special circumstances: hyperinfection, immune suppression, and travel history

The stakes rise considerably in hyperinfection or disseminated strongyloidiasis, which occurs almost exclusively in people whose immune systems are suppressed—by long-term corticosteroids, HTLV-1 co-infection, organ transplantation, or certain cancers and their treatments. In this setting, ivermectin remains the backbone of therapy, and albendazole is sometimes added as a companion drug, particularly when there is concern that gut malabsorption might blunt the effectiveness of oral therapy alone. Evidence for combination therapy in this severe form of the disease comes mainly from case series and expert clinical experience rather than large randomized trials, and it should be described honestly as a reasonable, guideline-supported approach rather than a rigorously proven superior strategy.

The more practical and preventable issue is screening. Anyone who has lived in or traveled extensively through an endemic region—even decades ago, even without ever having had symptoms—should be tested for Strongyloides before starting corticosteroids or other immunosuppressive therapy. This is a matter of ordinary personal responsibility and preparedness: a five-minute blood test before treatment can prevent a life-threatening hyperinfection later. Veterans, missionaries, refugees, and anyone with a rural agricultural background in a warm climate are groups worth particular attention, and a good physician will ask about this history rather than assume it is irrelevant simply because it happened long ago.

Key takeaway: Albendazole does have real activity against strongyloidiasis and is a legitimate, guideline-supported treatment when used correctly—typically 400 mg twice daily for seven days—but the honest evidence shows ivermectin cures the infection more reliably, so albendazole is best understood as the backup option a physician reaches for when ivermectin isn't suitable, not as the first choice.